Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Royal Bank of Canada cut shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a sector ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...